HER2+ mBC: Study Design and Results of DESTINY-Breast01

(4:56)

Dr. Dang on the DESTINY-Breast01 Trial in HER2+ Metastatic Breast Cancer

(1:42)

DESTINY-Breast01: a new “destiny” for HER2positive mBC patients?

(1:33)

Dr. Hurvitz on the Findings of DESTINY-Breast01 in HER2+ Metastatic Breast Cancer

(1:22)

Dr. Hamilton on the DESTINY-Breast01 Trial in HER2+ Breast Cancer

(1:7)

Kevin Kalinsky, MD, shares thoughts on the DESTINY-Breast01 clinical trial from SABCS 2020

(1:42)

HER2+ mBC: Addressing ILD in the DESTINY-Breast01 Study

(4:34)

Advanced HER2+ BC: Phase III HER2CLIMB and DESTINY-Breast01

(6:32)

Trastuzumab deruxtecan in patients with breast cancer and brain metastases in DESTINY-Breast01

(3:36)

Treatment Updated for HER2 Positive Breast Cancer: Changing Paradigms

(30:57)

Adam Brufsky, MD, PhD, elaborates on the clinical implications of DESTINY-Breast01 from SABCS 2020

(2:29)

Hope Rugo, MD, examines data from the DESTINY-Breast01 clinical study presented at SABCS 2020

(3:31)

HER 2-positiver, metastasierter Brustkrebs: DESTINY-Breast01 Studie mit Trastuzumab Deruxtecan

(5:6)

DESTINY-Breast03: T-DXd is superior to T-DM1 in HER2+ metastatic breast cancer

(2:48)

Trastuzumab deruxtecan in patients with breast cancer with brain metastases

(59)

DESTINY-Breast02: T-DXd in HER2+ metastatic breast cancer previously treated with T-DM1

(1:8)

Trastuzumab Deruxtecan for the Treatment of HER2+ Breast Cancer

(5:59)

Therapeutic landscape for patients with HER2-positive breast cancer with active brain metastases

(5:37)

Questions following the DESTINY-Breast trials

(2:26)

Updated survival results of DESTINY-Breast03: T-DXd vs T-DM1 in HER2+ metastatic breast cancer

(1:8)